Abstracts tagged "Preclinical Rheumatoid Arthritis"

Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 1650 • ACR Convergence 2021
Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis
Paolo Massimo Buscema¹, Giulia Massini², Francesca Della Torre², Masoud Asadi-Zeydabadi³, Colin O'Donnell⁴, Francis Newman⁵, Randall Tagg³, Weldon Lodwick⁵, Christopher Collora⁴, Marie Feser⁴, LauraKay Moss⁴, William Robinson⁶, Geoffrey Thiele⁷, Ted Mikuls⁷, Jess Edison⁸, V. Michael Holers⁴ and Kevin Deane⁹, ¹Semeion Research Center of Sciences of Communication; University of Colorado Denver Department of Mathematical and Statistical Sciences, Rome, Italy, ²Semeion Research Center of Sciences of Communication, Rome, Italy, ³University of Colorado Denver Department of Physics, Denver, CO, ⁴University of Colorado Denver, Aurora, CO, ⁵University of Colorado Denver Department of Mathematical and Statistical Sciences, Denver, CO, ⁶Stanford University, Palo Alto, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations of antibodies to citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and…
Abstract Number: 1651 • ACR Convergence 2021
Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis
Salina Haville¹, Jennifer Seifert¹, Saman Barzideh¹, LauraKay Moss¹, Navin Rao², Alyssa Johnsen³, Jane Buckner⁴, Eddie James⁵, Sylvia Posso⁴, Gary Firestein⁶, David Boyle⁷, William Robinson⁸, V. Michael Holers⁹ and Kevin Deane¹⁰, ¹University of Colorado Denver, Aurora, CO, ²Janssen R&D, Spring House, PA, ³Janssen R&D, Princeton Junction, NJ, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁶University of California San Diego, San Diego, CA, ⁷University of California San Diego, La Jolla, CA, ⁸Stanford University, Palo Alto, CA, ⁹University of Colorado, Denver, CO, ¹⁰University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period definable as elevations of antibodies to citrullinated protein antibodies (ACPA) before clinically-apparent inflammatory arthritis (IA). ACPA elevations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].